Summary: Citigroup initiated coverage of Evolent Health with a Buy recommendation and an average one-year price target representing a 54.39% upside. Fund sentiment indicates an increase in institutions reporting positions and a bullish outlook with a put/call ratio of 0.59. Major shareholders like Wellington Management Group Llp and Jpmorgan Chase have shown changes in their holdings.
Full article